Publications by authors named "Herman Roelink"
Article Synopsis
- The GOLIATH study is a 2-year clinical trial comparing two treatments for benign prostatic obstruction: transurethral resection of the prostate (TURP) and photoselective vaporization using the GreenLight XPS laser, with a focus on maintaining treatment effects seen at the 6-month mark over two years.
- The trial involved 281 patients across 29 centers in Europe and measured outcomes like the International Prostate Symptom Score and other health indicators, aiming to prove that GL-XPS is not inferior to TURP.
- Results showed that GL-XPS maintained similar effectiveness and safety compared to TURP over the two years, with fewer complications and comparable reductions in prostate size and specific antigen levels, though some
Purpose: We present the 1-year results of the GOLIATH prospective randomized controlled trial comparing transurethral resection of the prostate to GreenLight XPS for the treatment of men with nonneurogenic lower urinary tract symptoms due to prostate enlargement. The updated results at 1 year show that transurethral resection of the prostate and GreenLight XPS remain equivalent, and confirm the therapeutic durability of both procedures. We also report 1-year followup data from several functional questionnaires (OABq-SF, ICIQ-SF and IIEF-5) and objective assessments.
View Article and Find Full Text PDFBackground: The comparative outcome with GreenLight (GL) photoselective vaporisation of the prostate and transurethral resection of the prostate (TURP) in men with lower urinary tract symptoms due to benign prostatic obstruction (BPO) has been questioned.
Objective: The primary objective of the GOLIATH study was to evaluate the noninferiority of 180-W GL XPS (XPS) to TURP for International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax) at 6 mo and the proportion of patients who were complication free.
Design, Setting, And Participants: Prospective randomised controlled trial at 29 centres in 9 European countries involving 281 patients with BPO.